Groupe d'Etude en Oncologie du Quebec

Title	A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
Protocole ID	CA244-0001
ClinicalTrials.gov ID	NCT06618287
Cancer Type(s)	Non Small Cells - Lung Small Cells - Lung
Phase	Phase I-II
Stage
Study Type	Clinical
Drug	BMS-986507 avec osimertinib et BMS-986507 avec pembrolizumab
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
City
Principal Investigator	Dr. Jennifer Friedmann
Coordinator	Karima Khebab 514-340-8222 poste 26187
Status	Recruiting
Activation Date
Eligibility Criteria	Participants must have at least one measurable lesion per response evaluation criteria in solid tumors. Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. Participants must have a life expectancy of at least 3 months at the time of the first dose.
Exclusion Criteria	Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology. Participants must not have any untreated symptomatic central nervous system (CNS) metastases. Participants must not have a history of serious recurrent infections. Participants must not have a history of severe heart disease. Other protocol-defined Inclusion/Exclusion criteria apply.

Groupe d'étude en oncologie du Québec